Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (July 2020)
16 slides from Harrow's investor presentation, Jul 9, 2020
Slide 1: Harrow - July 2020
JULY 2020 HARROW NASDAQ: HROW OUTSTANDING COMMON STOCK: 25.6M SHARES ESTIMATED MARKET CAPITALIZATION $131M PRICE PER SHARE as of July 7, 2020 $5.13
Slide 2: Safe Harbor
HARROW SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying
Slide 3: Introduction
Introduction HARROW We start-up innovative healthcare businesses. We own and operate ImprimisRx, an ophthalmology-focused prescription pharmaceutical platform. We actively participate and manage our interests in six other healthcare businesses we founded. We own royalty streams on drug candidates be
Slide 4: Consolidated Revenues, Assets, and Gross Margins
Introduction Consolidated Revenues, Assets, and Gross Margins $70,000 (Revenue and Assets in Thousands) $60,000 $50,000 $40,000 $30,000 $20,000 $10,000 $0 2014 2015 2016 2017 2018 2019 AdJ.E(L)BITDA —-($7.5M) ($10M) ($10M) ($7M) $0.2M $4.6M Mim Consolidated Revenues Mm Assets === Gross Margins HARRO
Slide 5: ImprimisRx
IMPrimIs p * 100% wholly-owned and operated Harrow subsidiary, founded in 2014. + Nation’s leading FDA-registered ophthalmology-focused cGMP pharmaceutical drug compounder and prescription drug platform serving the ocular surgery, dry eye disease, and glaucoma markets. * Launched over 7 new ophthalm
Slide 6: Traditional Pharmaceutical Value Chain
Our Businesses Traditional Pharmaceutical Value Chain oe ea ee &- MD/Hospital PRODUCTION PHARMACY INSURERS WHOLESALERS PHARMACY es BENEFIT RETAILERS ——§ seit tliat Prescription NOs HOSPITAL OR ASC Middle-men and intermediaries thrive. Inefficiencies diminish value for the patient, pharmaceutical com
Slide 7: ImprimisRx Value Chain
Our Businesses ImprimisRx Value Chain — (A) PATIENT ORDER & (@) PAYMENT > MD OFFICE, —=- HOSPITAL OR ASC Cash-pay focused; no pharmacy benefit manager (PBM), wholesaler or distributor middlemen. No formulary rejections, discount cards, payment submittals, investigations or PBM claw-backs. Minimizes
Slide 8: ImprimisRx Opportunity and Growth Strategy
IMPrimis 2. Opportunity *« Dominate share of pharmaceutical products used in US ophthalmic surgery (SM+ annual procedures). * Expand >10% market share* in ophthalmic inflammation and infection (refractive surgeries). -« Announced supply agreements in Q1 2020 with providers of ~250K annual procedures
Slide 9: Non-Controlled Equity Interests
Our Businesses Non-Controlled Equity Interests HARROW elon PHARMACEUTICALS Ss melt PHARMACEUTICALS ESTIMATED VALUE: $48M* y y f = “Melt/Surface equity values estimated based on the conversion price of Series A preferred stock (the most recent financing; and not a US. GAAP measure); Eton value is cal
Slide 10: Eton Pharmaceuticals
elon PHARMACEUTICALS Background * Specialty pharmaceutical company; with diversified and growing pipeline. * Deconsolidated from Harrow in June 2017, NASDAQ IPO in November 2018 (ETON). « Harrow Health owns 3.5M shares of Eton common stock (-17%). Opportunity* * $2.5B+ aggregate market opportunity f
Slide 11: Surface Pharmaceuticals
Our Businesses Gurface Background * Clinical stage pharmaceutical development company focused on ocular surface and dry eye disease. * Deconsolidated from Harrow May 2018 after $21M Preferred Stock Offering led by Flying L Partners. « Harrow Health owns 3.5M shares of Surface common stock (~30%). Op
Slide 12: Melt Pharmaceuticals
melt PHARMACEUTICALS. Background * Clinical-stage company developing patented sublingual non-lV, non-opioid sedation drug candidates. * Deconsolidated from Harrow in January 2019 after $11M Preferred Stock Offering. * Harrow Health owns 3.5M shares of Melt common stock (-44%). Opportunity * Cataract
Slide 13: Mayfield and Stowe
Our Businesses MAN ARIE LD Background Women’s health pharmaceutical company developing three novel drug candidates: *« MAY-66: Topical NCE for bacterial vaginosis «+ MAY-44: Temporary treatment of dyspareunia + MAY-88: Treatment for interstitial cystitis Opportunity Transformative patented therapies
Slide 14: Visionology
& visionology Background Comprehensive, on-demand ophthalmic care platform. - Innovative telemedicine 2.0 platform “hugs” patient with patent-pending Circle of Care™ program. * On-demand consultations with eye health professionals; pairing patient with trusted local doctor. + Harrow currently contro
Slide 15: Harrow
HARROW ¢ ImprimisRx is a cornerstone wholly-owned ophthalmology-focused commercial drug platform. « Expect ImprimisRx to grow beyond a $100M revenue business over the next few years. « Leverage ImprimisRx ophthalmic drug platform to partner and inorganically expand our business. « Positioned to capt
Slide 16: Contact
HARROW 102 Woodmont Blvd. Ste 610 Nashville, Tennessee 37205 (615) 733-4730 IR@HARROWINC.COM WWW.HARROWINC.COM